DOI: 10.6084/m9.figshare.12085155.v1
title: Additional file 1 of MSX2 suppression through inhibition of TGFβ signaling enhances hematopoietic differentiation of human embryonic stem cells

description: Additional file 1 : Figure S1. MSX2 is suppressed upon inhibition of TGFβ signaling during hematopoietic differentiation of hESCs. (A) Heatmap showing down-regulated TFs upon SB treatment. (B) TFs that were predicted to be upstream of the suppressed hematopoiesis-associated genes. The size and color of the bubble indicate combined score and p-value of the predicted term. (C) The real-time PCR analysis of the signature genes of each population in undifferentiated hESCs, MEs (APLNR+), HEPs (CD31 + CD34+) and HPCs (CD43+) generated from hESCs after hematopoietic differentiation. Relative expression is normalized to the level (=1) of undifferentiated hESCs. Results are shown as means ±SD (n = 3). Figure S2. MSX2 deletion augments the hematopoietic differentiation of hESCs. (A) Schematic overview showing the experimental design to determine the hematopoietic potential of APLNR+ mesoderm cells. APLNR+ cells were sorted at day 2 of hematopoietic differentiation and seeded into the hematopoietic culture for 5 days before CD43 flow cytometry analysis. (B) Flow cytometry analysis showing the generation of CD43+ HPCs emerging from H1 WT and H1 MSX2−/− APLNR+ cells. Figure S3. MSX2 deletion had no effect on BMP, WNT and FGF signaling. (A) GSEA of WNT signaling between WT and MSX2−/− cells. (B) GSEA of BMP signaling between WT and MSX2−/− cells. (C) GSEA of FGF signaling between WT and MSX2−/− cells. Figure S4. MSX2 mediates the function of TGFβ signaling during EHT. (A) Left panel: Flow cytometry analysis showing the percentage of CD43+ cells from H1 cells with or without MSX2 overexpression in the absence or presence of SB-431542 at day 8 of hematopoietic differentiation. Right panel: The fold increase of CD43+ cell generation from H1 cells with or without MSX2 overexpression after SB treatment. (B) Left panel: Flow cytometry analysis showing the percentage of CD43+ subpopulation gated on CD31+ cells from H1 cells with or without MSX2 overexpression in the absence or presence of SB-431542 at day 8 of hematopoietic differentiation. Right panel: The fold increase of CD43+ subpopulation generation gated on CD31+ cells from H1 cells with or without MSX2 overexpression after SB treatment. (C) Left panel: Flow cytometry analysis showing the percentage of CD43+ cells from H1 WT and H1 MSX2−/− cells with or without TGFβ1 treatment at day 8 of hematopoietic differentiation. Right panel: The fold increase of CD43+ cell generation from H1 WT and H1 MSX2−/− cells after TGFβ1 treatment. (D) Left panel: Flow cytometry analysis showing the percentage of CD43+ subpopulation gated on CD31+ cells from H1 WT and H1 MSX2−/− cells with or without TGFβ1 treatment at day 8 of hematopoietic differentiation. Right panel: The fold increase of CD43+ subpopulation generation gated on CD31+ cells from H1 WT and H1 MSX2−/− cells after TGFβ1 treatment. (E) Real-time PCR analysis of MSX2 in H1 hESCs expressing ishMSX2–1, ishMSX2–2 or expressing a scramble shRNA (ishScramble) after the addition of DOX (2 μg/ml) during the transition from HEP to HPCs. All values are normalized to the level (= 1) of mRNA in H1 hESCs expressing a scramble shRNA (ishScramble). (F) Left panel: Flow cytometry analysis showing the percentage of CD43+ cells from H1 ishScramble and H1 MSX2-knockdown cells after the addition of DOX (2 μg/ml) during the transition from HEP to HPCs with or without TGFβ1 treatment. Right panel: The fold increase of CD43+ cell generation from H1 ishScramble and H1 MSX2-knockdown cells after TGFβ1 treatment. (G) Left panel: Flow cytometry analysis showing the percentage of CD43+ subpopulation gated on CD31+ cells from H1 ishScramble and H1 MSX2-knockdown cells after the addition of DOX (2 μg/ml) during the transition from HEP to HPCs with or without TGFβ1 treatment. Right panel: The fold increase of CD43+ subpopulation generation gated on CD31+ cells H1 ishScramble and H1 MSX2-knockdown cells after TGFβ1 treatment.